TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32231293

Group type: EXPERIMENTAL
Intervention: FEC14 (fluorouracil, epirubicin and cyclophosphamide administered every 2 weeks)
Number of subjects: 1214

Group type: COMPARATOR
Intervention: FEC21 (fluorouracil, epirubicin and cyclophosphamide administered every 3 weeks)
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: FEC14
Number of subjects: 1214

Group type: COMPARATOR
Intervention: FEC21
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: FEC14 (in hormone receptor-negative tumours)
Number of subjects: 1214

Group type: COMPARATOR
Intervention: FEC21 (in hormone receptor-negative tumours)
Number of subjects: 1214
Study: 34111699

Group type: EXPERIMENTAL
Intervention: Emotion regulation training (cognitive or behavioral approach)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 108
Study: 32183798

Group type: EXPERIMENTAL
Intervention: Blended learning training programme
Number of subjects: 17
Study: 34768453

Group type: EXPERIMENTAL
Intervention: Perineal massage and EPI‐NO® device group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Self‐massage group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 32312333

Group type: EXPERIMENTAL
Intervention: Garlic powder supplementation (400 mg per tablet, 4 tablets daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (400 mg starch per tablet, 4 tablets daily)
Number of subjects: 90
Study: 35162482

Group type: EXPERIMENTAL
Intervention: Home midwifery assistance for one month after birth
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 51
Study: 34922726

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg plus Codeine 30 mg (group APAP/COD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg (group IBU)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (group PLA)
Number of subjects: 120
Study: 35781789

Group type: EXPERIMENTAL
Intervention: Ultra-rapid lispro (URLi)
Number of subjects: 673

Group type: COMPARATOR
Intervention: lispro (Humalog)
Number of subjects: 673
Study: 32372432

Group type: EXPERIMENTAL
Intervention: 3% EF
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 6% EF
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 9% EF
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (0% EF)
Number of subjects: 72
Study: 35562226

Group type: EXPERIMENTAL
Intervention: i.v. bolus remimazolam (0.02–0.27 mg kg−1)
Number of subjects: 120
Study: 34852952

Group type: EXPERIMENTAL
Intervention: Thymepearls (TP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 35126629

Group type: EXPERIMENTAL
Intervention: EM algorithm (algorithm group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: RAMP algorithm
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mean filter
Number of subjects: 120

Group type: COMPARATOR
Intervention: PWLS algorithm
Number of subjects: 120

Group type: COMPARATOR
Intervention: MS-PWLS algorithm
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: EM algorithm
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ADPKD
Number of subjects: 120
Study: 34109365

Group type: EXPERIMENTAL
Intervention: Modified posterior dental splint
Number of subjects: 89

Group type: COMPARATOR
Intervention: Stabilization splint
Number of subjects: 89
Study: 36091061

Group type: EXPERIMENTAL
Intervention: Prenatal depression
Number of subjects: 30

Group type: COMPARATOR
Intervention: Peritraumatic distress
Number of subjects: 30

Group type: COMPARATOR
Intervention: Perceived stress
Number of subjects: 30
Study: 33753893

Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional diet
Number of subjects: 52
Study: 32981298

Group type: COMPARATOR
Intervention: Low glucocorticoid users (0< DDDs ≤45)
Number of subjects: 1896159

Group type: COMPARATOR
Intervention: Intermediate glucocorticoid users (45< DDDs ≤90)
Number of subjects: 1896159

Group type: COMPARATOR
Intervention: High glucocorticoid users (90< DDDs)
Number of subjects: 1896159
Study: 34495079

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (nasal strips) for 6 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (nasal strips)
Number of subjects: 100
Study: 32126267

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (20 mg/m2) with postoperative radiation therapy (total dose 60-66 Gy)
Number of subjects: 91
Study: 36096354

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Icare rebound tonometry
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Pneumatonometry
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Rebound tonometry
Number of subjects: 135
Study: 32139240

Group type: EXPERIMENTAL
Intervention: Improvement in FRIEND%PRED (age-predicted VO2peak)
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Every 1 unit % increase in FRIEND%PRED
Number of subjects: 1283
Study: 35926726

Group type: EXPERIMENTAL
Intervention: Hexavalent live human-bovine reassortant rotavirus vaccine (HRV)
Number of subjects: 6400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6400
Study: 32031889

Group type: EXPERIMENTAL
Intervention: MK-2206 135 mg/week
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control (standard taxane- and anthracycline-based neoadjuvant therapy)
Number of subjects: 151
Study: 36193841

Group type: EXPERIMENTAL
Intervention: Baseline insulin level
Number of subjects: 214
Study: 32255279

Group type: EXPERIMENTAL
Intervention: Frozen mixed serum potassium candidate reference materials
Number of subjects: 0
Study: 34634445

Group type: EXPERIMENTAL
Intervention: Integrative Body‐Mind‐Spirit (IBMS)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Qigong
Number of subjects: 281

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 281
Study: 33058798

Group type: EXPERIMENTAL
Intervention: Cefiderocol 2 g every 8 hours for 7–14 days
Number of subjects: 300

Group type: COMPARATOR
Intervention: Meropenem 2 g every 8 hours for 7–14 days
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 300

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 300
Study: 32726308

Group type: EXPERIMENTAL
Intervention: Visual Clinical Decision Support System (CDSS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard Consultations (SDR)
Number of subjects: 31
Study: 35340578

Group type: EXPERIMENTAL
Intervention: DSN-led pathway
Number of subjects: 162

Group type: COMPARATOR
Intervention: GP routine follow-up
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 162
Study: 33794804

Group type: EXPERIMENTAL
Intervention: FIT-HIP intervention (multicomponent cognitive behavioral intervention)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 39
Study: 35999682

Group type: EXPERIMENTAL
Intervention: Self-etch adhesive system
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional acid-etch
Number of subjects: 47
Study: 34376180

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) TXA
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: TXA in a PAMC injection for topical administration
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combination of both intravenous and topical administration of TXA
Number of subjects: 240

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 240
Study: 34111690

Group type: EXPERIMENTAL
Intervention: Dosed exercise
Number of subjects: 302

Group type: COMPARATOR
Intervention: Health education intervention
Number of subjects: 302
Study: 35135310

Group type: EXPERIMENTAL
Intervention: Ivermectin, doxycycline, zinc, vitamins D and C
Number of subjects: 24
Study: 33794789

Group type: EXPERIMENTAL
Intervention: DemStepCare intervention (complex intervention with GP support by a multi-professional team)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual care (slightly expanded)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Aggregated routine data from German health insurance companies (second control group)
Number of subjects: 800
Study: 32092309

Group type: EXPERIMENTAL
Intervention: Upadacitinib 7.5 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 33201120

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 246
Study: 33646842

Group type: EXPERIMENTAL
Intervention: Rapid intermittent bolus of hypertonic saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow continuous infusion of hypertonic saline
Number of subjects: 0
Study: 36078774

Group type: EXPERIMENTAL
Intervention: Training (16 weeks of combined training including walking/running at 63% of V˙O2max, three times per week, and strength training, consisting of one set of fifteen repetitions at moderate intensity, twice per week)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (remained physically inactive)
Number of subjects: 52
Study: 33347829

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy (carboplatin and pemetrexed)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 419
Study: 32957403

Group type: EXPERIMENTAL
Intervention: Self-developed pelvic floor repair system
Number of subjects: 132

Group type: COMPARATOR
Intervention: Avaulta repair system
Number of subjects: 132
Study: 36123052

Group type: EXPERIMENTAL
Intervention: Afya conditional cash transfer (CCT) intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 34736394

Group type: EXPERIMENTAL
Intervention: Individualized telephone-based care support (ITBCS) program for 3 months followed by 6 months of follow-up consultations.
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual care services available for caregivers.
Number of subjects: 168
Study: 36340667

Group type: EXPERIMENTAL
Intervention: Intrauterine injection of autologous PRP
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard treatment of fetal transfer without intrauterine PRP injection
Number of subjects: 118
Study: 32041649

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35410938

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXY) spray (24 IU)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (PLC) spray plus oral naltrexone (NTX) (50 mg)
Number of subjects: 62
Study: 34268680

Group type: EXPERIMENTAL
Intervention: 16-week supervised exercise program (strength and aerobic training) starting 7-14 days after surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 80
Study: 35329972

Group type: EXPERIMENTAL
Intervention: Daily supplementation with a new nutritional product developed by the Grand Fontaine Laboratories
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard renal dietary advice (Control)
Number of subjects: 0
Study: 32126557

Group type: EXPERIMENTAL
Intervention: Mobile teledermoscopy-enhanced skin self-examinations (SSEs)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Naked-eye skin self-examinations (SSE)
Number of subjects: 28
Study: 32762573

Group type: EXPERIMENTAL
Intervention: Self-report logbooks of exercise performance
Number of subjects: 15
Study: 33728044

Group type: EXPERIMENTAL
Intervention: Medicines and Alcohol Consultation (MAC) intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (consultations as usual)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Follow-up calls (telephone)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Data collection methods (telephone and postal)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: External researcher follow-up
Number of subjects: 51
Study: 35064716

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg for 7 days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg single dose
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Escitalopram plasma levels
Number of subjects: 59
Study: 33736756

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Amiodarone (Ischemic)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (Ischemic)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Amiodarone (Nonischemic)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (Nonischemic)
Number of subjects: 100
Study: 32058140

Group type: EXPERIMENTAL
Intervention: App-based audio guidance pelvic floor muscle training
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional home-based pelvic floor muscle training
Number of subjects: 108
Study: 35448154

Group type: EXPERIMENTAL
Intervention: Intensive arm (8 phone counseling sessions + 8 weeks of nicotine replacement therapy)
Number of subjects: 818

Group type: COMPARATOR
Intervention: Minimal arm (3 sessions + 2 weeks of nicotine replacement therapy)
Number of subjects: 818
Study: 32245369

Group type: EXPERIMENTAL
Intervention: HR‐HPV test
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Visual Inspection under Acetic Acid (VIA)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 469
Study: 34052928

Group type: EXPERIMENTAL
Intervention: Infrared laser treatment (0.6 J per point, 214.28 J/cm2 energy density, 17.85 W/cm2 intensity)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Red laser treatment (0.6 J per point, 214.28 J/cm2 energy density, 17.85 W/cm2 intensity)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 45
Study: 33722758

Group type: EXPERIMENTAL
Intervention: Greedy Rabbit exergame (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo version of Greedy Rabbit (control group)
Number of subjects: 60
Study: 33571562

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-exercise control group (NET)
Number of subjects: 42
Study: 33821439

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) with a load of 70% of maximum inspiratory pressure (MIP), 3 sets of 30 repetitions with 1-min intervals
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group performing IMT without load
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 40
Study: 34152784

Group type: EXPERIMENTAL
Intervention: Culturally targeted loss-framed messaging
Number of subjects: 457

Group type: COMPARATOR
Intervention: Standard loss-framed messaging
Number of subjects: 457
Study: 35821731

Group type: EXPERIMENTAL
Intervention: Rapid Treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 25
Study: 35212136

Group type: EXPERIMENTAL
Intervention: Intralesional Purified Protein Derivative (PPD) 10 IU (0.1 ml)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intralesional Zinc Sulfate 2%
Number of subjects: 120
Study: 32356170

Group type: EXPERIMENTAL
Intervention: Subacromial corticosteroid injection (SCI)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Subacromial corticosteroid injection plus suprascapular nerve block (SSNB)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (SCI)
Number of subjects: 66
Study: 33270009

Group type: COMPARATOR
Intervention: Usual care plus static text messages (n=59)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: One-intervention arm (n=57)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Two-intervention arm (n=58)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Electronic cigarettes in Australia
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Nicotine replacement treatment in England
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Structured Planning and Prompting Protocol coping strategies
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Online intervention
Number of subjects: 235
Study: 33439419

Group type: EXPERIMENTAL
Intervention: Intervention group (n=70)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Waitlist control group (n=103)
Number of subjects: 173
Study: 33170261

Group type: EXPERIMENTAL
Intervention: Sodium Benzoate (500 mg twice daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 34825368

Group type: EXPERIMENTAL
Intervention: Social distancing intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomization-based inference methods
Number of subjects: 0
Study: 34435202

Group type: EXPERIMENTAL
Intervention: High altitude exposure (HA)
Number of subjects: 483
Study: 32438300

Group type: EXPERIMENTAL
Intervention: Home enteral nutrition (HEN) for 4 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard enteral nutrition (SEN)
Number of subjects: 62
Study: 34468080

Group type: EXPERIMENTAL
Intervention: Filgotinib (200 mg once daily for 11 days)
Number of subjects: 27
Study: 34501669

Group type: EXPERIMENTAL
Intervention: Virtual Environment (VE) rehabilitation program
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard paper–pencil treatment
Number of subjects: 35
Study: 34585443

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 7714

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7714
Study: 35293973

Group type: EXPERIMENTAL
Intervention: Early supplemental parenteral nutrition (E‐SPN) starting on day 3 after surgery
Number of subjects: 230

Group type: COMPARATOR
Intervention: Late supplemental parenteral nutrition (L‐SPN) starting on day 8 after surgery
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: E‐SPN
Number of subjects: 230
Study: 33710368

Group type: EXPERIMENTAL
Intervention: UBR5 expression combined with CD163+ tumor-associated macrophages (TAMs)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Integration of UBR5 and CD163
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Incorporation of UBR5 and CD163 into clinical indicators TNM stage or SSIGN
Number of subjects: 310

Group type: COMPARATOR
Intervention: UBR5 expression
Number of subjects: 310

Group type: COMPARATOR
Intervention: CD163 expression
Number of subjects: 310
Study: 32113839

Group type: EXPERIMENTAL
Intervention: GCs + LEF (20 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: GCs monotherapy
Number of subjects: 66
Study: 36094619

Group type: EXPERIMENTAL
Intervention: AUT00206
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 32141188

Group type: EXPERIMENTAL
Intervention: Healthy eating blog intervention (n = 42)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (n = 42)
Number of subjects: 84
Study: 33272923

Group type: EXPERIMENTAL
Intervention: Parental smoking practices (number of smokers in the home)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Parental smoking practices (smoking inside the house)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Families who smoke only outside the home
Number of subjects: 213
Study: 36232122

Group type: EXPERIMENTAL
Intervention: Gene therapy with intramuscular injections of pIRES/VEGF165/HGF plasmids and 1 month of ANG-1 plasmids
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gene therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 34894884

Group type: EXPERIMENTAL
Intervention: Mindfulness-based attention training (MBAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lifestyle education (LifeEd)
Number of subjects: 0
Study: 32949941

Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (VR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: iPad control condition
Number of subjects: 90
Study: 35244019

Group type: EXPERIMENTAL
Intervention: Hysteroscopic treatment of Asherman syndrome
Number of subjects: 43
Study: 33781673

Group type: EXPERIMENTAL
Intervention: Telemedicine consultations
Number of subjects: 253

Group type: COMPARATOR
Intervention: Face-to-face consultations
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Non-presential consultations
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Contact preference
Number of subjects: 253
Study: 35619138

Group type: EXPERIMENTAL
Intervention: Policy briefs signed by the African donor organization (financial authority)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Policy briefs signed by the African university (scientific authority)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Policy briefs signed by North American/European organizations (financial and scientific authority)
Number of subjects: 0
Study: 33280497

Group type: EXPERIMENTAL
Intervention: MAP17 overexpression group
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: MAP17 knockdown group
Number of subjects: 3

Group type: COMPARATOR
Intervention: Negative control group
Number of subjects: 3
Study: 35302301

Group type: EXPERIMENTAL
Intervention: Probiotic milk (Yakult)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Probiotic powder (enKor-D)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 34
Study: 32876780

Group type: EXPERIMENTAL
Intervention: ABP 798
Number of subjects: 311

Group type: COMPARATOR
Intervention: Rituximab reference product (RP)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Rituximab US transitioning to ABP 798
Number of subjects: 311

Group type: COMPARATOR
Intervention: Rituximab EU
Number of subjects: 311
Study: 36117569

Group type: EXPERIMENTAL
Intervention: Active non-invasive transcutaneous electrical stimulation of greater occipital nerve (NITESGON)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham NITESGON
Number of subjects: 100

Group type: COMPARATOR
Intervention: Active NITESGON with local anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Active NITESGON on the C5/C6 nerve
Number of subjects: 100